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In a recent paper, Verma et al. reported abnormal been shown to improve endothelium-dependent vasomo-
endothelium-dependent relaxation to acetylcholine in iso- tion [2,3].
lated internal mammary arteries obtained from patients Second, the authors refer to atherosclerosis of the
with coronary artery disease [1]. The authors also observed internal mammary artery (IMA). However, even in patients
a moderate increase of the maximum response but not of with atherosclerosis in the coronary circulation, atheros-
the sensitivity of these relaxations after 20 min of incuba- clerotic structural changes rarely occur in the IMA [4,5]
tion with micromolar concentrations of either bosentan, a making it the conduit of choice for coronary bypass
non-selective ET receptor antagonist, BQ-123 (an ET surgery. It is known that atherosclerotic changes mayA
selective compound) or BQ-788 (an ET selective com- develop after this artery has been grafted as a bypassB
pound at low concentrations). The improvement of endo- conduit or in cardiac transplant recipients [6]. Therefore,
thelium-dependent relaxation averaged between 10 and the authors’ notion that ‘ET-1 is increased in atheros-
17% of complete relaxation compared to control experi- clerotic IMA’ is hard to follow.
ments, and was not present in endothelium-denuded ves- Third, endothelium-dependent relaxation in this vessel
sels and not evident in response to the endothelium- has been extensively studied, and most studies, including
independent vasodilator sodium nitroprusside according to our own, have shown that endothelium-dependent relaxa-
the authors’ unpublished data. The authors concluded that tion in response to acetylcholine is preserved in the IMA
both ET and ET receptors contribute to ‘endothelial [7–10]. How can the clearly abnormal relaxant response toA B
dysfunction’ and that blocking both the ET and the ET acetylcholine, reaching relaxation of only 40% of pre-A B
receptor may have endothelial protective effects in human contraction, observed in the authors’ experiments be
internal mammary arteries. However, there are several explained? The authors refer to one previous study on
issues that must be taken into account when interpreting endothelium-dependent relaxation in human IMA, which
these data. showed relaxant responses between 0 and 70% despite
First, the clinical characteristics and treatments of the comparable ecNOS immunostaining in histologic sections
study patients, a considerable number of which were in the vessels investigated [11]. Not surprisingly, vessel
women, deserve mentioning. More than half of the patients culture for 24 h with sepiapterin or L-arginine had no effect
had a positive family history for coronary artery disease, on the relaxant response which was abnormal to begin with
were smokers, and/or had hypercholesterolemia. It is [11]. The aforementioned study and the one by Verma et al.
surprising to learn that despite the elevated plasma lipids are in strong contrast to several other studies by different
and in view of the beneficial effects of statins in the laboratories demonstrating preserved endothelium-depen-
secondary prevention of coronary artery disease, none of dent relaxation in response to acetylcholine in human IMA
the patients was on statin therapy, a treatment that has also [7–9,12,13].
As correctly pointed out in the editorial by Hoogerwerf
[14], careful intraoperative handling of the arteries is ofqPII of original article: S0008-6363(00)00244-3 paramount importance for the functional integrity of the
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studies revealed that intraoperative handling of the graft is that blockade of ET receptors improves NO bioactivityA
a crucial determinant of endothelium-dependent responses and endothelium-dependent NO-mediated relaxation in the
in the IMA and also in other grafts [8,10]. Using acetyl- thoracic aorta of atherosclerotic apolipoprotein-deficient E
choline as a stimulus, it has been demonstrated that mice [24]. Similarly, indices of increased NO bioactivity
endothelium-dependent relaxations average between 75 have been found after ET blockade in coronary effluents of
and more than 95% of precontraction in arteries obtained perfused rat hearts, and similar effects were seen with ETA
from CAD patients with multiple risk factors [7–9,12,13]. selective and non-selective ET /ET receptor antagonists.A B
This notion is also supported by a study demonstrating that Interestingly, no effect was observed with selective ETB
mechanical manipulation such as distension does indeed receptor blockade alone [25]. In humans ET blockadeA
impair endothelial-dependent responses to acetylcholine improves NO-mediated vascular function in the brachial
[16]. artery in vivo which can be blocked by ET receptorB
In their article, the authors repeatedly refer to ‘endotheli- blockade [26], and in a recent clinical study, improved
al dysfunction’ as simply the ‘net balance of endothelium- acetylcholine-mediated vasomotion in coronary arteries of
derived vasoconstriction and vasodilation’. Although at- patients with coronary atherosclerosis after treatment with
tractive, this view does not take into account the complexi- the ET receptor antagonist BQ-123 has been demon-A
ty of the abnormalities occurring in the injured endo- strated [27]. Taken together, the results from these studies
thelium [17] determining the endothelial phenotype. Thus, strongly are consistent with the concept that ET and notA
impairment of NO-mediated endothelium-dependent relax- ET receptors are responsible for increases in NO bioac-B
ation represents only one aspect of the spectrum of tivity after acute or chronic ET receptor blockade.
‘endothelial dysfunction’ which comprises the dysregula- As endothelin receptor antagonists are reaching the
tion of all endothelial cell functions, including cytokine clinical arena, the therapeutic potential of this new class of
release, lipid metabolism, morphological cellular changes, drugs must be carefully assessed [28]. Combined ET
disturbances of coagulation, etc. [17,18]. Abnormal endo- receptor antagonists, including bosentan, have unques-
thelium-dependent vasomotion as part of ‘endothelial tionably provided a great step in the therapy of patients
dysfunction’ not only occurs in atherosclerosis, but also in with advanced congestive heart failure. The majority of
conditions such as heart failure and pulmonary hyperten- studies, experimental ones as well as clinical ones, inves-
sion. Several previous studies have shown that ET receptor tigating physiopathologies such as heart failure, endo-
blockade can improve or even reverse this abnormality thelium-dependent vasomotion, and hypertension, have
(reviewed in Ref. [19]). shown beneficial effects through blockade of the ETA
Finally, the authors claim an ‘equal contribution of both receptor, in most cases irrespective whether the ETB
ET and ET receptors towards endothelial function in receptor was blocked or not. The data presented by VermaA B
human IMA’ based on their observations of responses to et al. essentially support this notion, demonstrating com-
acetylcholine in absence or presence of receptor specific parable effects between the ET selective antagonist BQ-A
ET antagonists. Moreover, demonstrating a 13% increase 123 and bosentan on endothelium-dependent vasomotion.
in endothelium-mediated relaxation after acute ET re-B
ceptor blockade with BQ-788 at a concentration of 1
mmol / l, the authors interpret this finding as: (a) ETB References
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